EURACAN/IASLC关于更新胸膜间皮瘤组织学分类的建议:迈向多学科方法
欧洲罕见成人实体癌网络/国际肺癌研究协会赞助的多学科小组于2018年开会批判性审查当前分类,提出14条建议,包括更新分类以纳入架构模式、基质和细胞学特征以细化预后,常规进行上皮样亚型分级,报告有利/不利组织学特征,整合临床相关分子数据,标准化影像采集和术语,多学科肿瘤委员会应包括病理学家,所有组织学亚型均应考虑化疗,肉瘤样或双相型患者不应被排除一线临床试验,不推荐无家族史时系统筛查胚系突变。
要点
- 分类应更新纳入架构模式、基质和细胞学特征以细化预后。
- 上皮样恶性胸膜间皮瘤应常规分级,并报告有利/不利组织学特征。
- 所有组织学亚型均应考虑化疗,肉瘤样或双相型不应被排除一线临床试验。
核心结论
- 这些多学科病理分类和应用建议将允许更有信息量的病理报告和潜在风险分层,以支持临床实践、研究和临床试验。
研究设计与样本
- 多学科小组(病理学家、分子生物学家、外科医生、放射科医生和肿瘤学家)由欧洲罕见成人实体癌网络/国际肺癌研究协会赞助,于2018年开会批判性审查当前分类。
主要发现
- 建议包括:分类应更新以纳入架构模式、基质和细胞学特征以细化预后;在数据积累前提下,原位恶性间皮瘤可作为附加类别;上皮样恶性胸膜间皮瘤应常规分级;应常规报告有利/不利组织学特征;如进行,临床相关分子数据(程序性死亡配体1、BRCA1相关蛋白1[BAP1]和细胞周期蛋白依赖性激酶抑制剂2A)应纳入报告;其他分子数据应作为未来试验的一部分积累;切除标本(即扩展胸膜切除/剥脱术和胸膜外全肺切除术)应进行病理分期,较小标本进行临床分期;理想情况下,应从胸膜腔至少三个不同区域取样,包括术前影像识别的感兴趣区域;影像采集协议/影像术语应标准化以辅助研究/细化临床分期;多学科肿瘤委员会应包括病理学家以确保考虑适当治疗选择;所有组织学亚型均应被视为化疗的潜在候选者;肉瘤样或双相型间皮瘤患者不应被排除一线临床试验,除非有令人信服的理由;肿瘤亚型应进一步评估与免疫治疗反应持续时间的关系;不推荐无BAP1综合征可疑家族史时系统筛查所有患者的胚系突变。
临床怎么用
- 病理报告应更新以纳入架构模式、基质和细胞学特征、分级、有利/不利组织学特征以及临床相关分子数据(如进行)。
- 多学科肿瘤委员会应包括病理学家,所有组织学亚型均应考虑化疗,肉瘤样或双相型患者不应被排除一线临床试验。
- 切除标本应进行病理分期,较小标本进行临床分期;理想情况下从胸膜腔至少三个不同区域取样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Molecular and immunologic breakthroughs are transforming the management of thoracic cancer, although advances have not been as marked for malignant pleural mesothelioma where pathologic diagnosis has been essentially limited to three histologic subtypes. METHODS: A multidisciplinary group (pathologists, molecular biologists, surgeons, radiologists, and oncologists), sponsored by European Network for Rare Adult Solid Cancers/International Association for the Study of Lung Cancer, met in 2018 to critically review the current classification. RESULTS: Recommendations include: (1) classification should be updated to include architectural patterns and stromal and cytologic features that refine prognostication; (2) subject to data accrual, malignant mesothelioma in situ could be an additional category; (3) grading of epithelioid malignant pleural mesotheliomas should be routinely undertaken; (4) favorable/unfavorable histologic characteristics should be routinely reported; (5) clinically relevant molecular data (programmed death ligand 1, BRCA 1 associated protein 1 [BAP1], and cyclin dependent kinase inhibitor 2A) should be incorporated into reports, if undertaken; (6) other molecular data should be accrued as part of future trials; (7) resection specimens (i.e., extended pleurectomy/decortication and extrapleural pneumonectomy) should be pathologically staged with smaller specimens being clinically staged; (8) ideally, at least three separate areas should be sampled from the pleural cavity, including areas of interest identified on pre-surgical imaging; (9) image-acquisition protocols/imaging terminology should be standardized to aid research/refine clinical staging; (10) multidisciplinary tumor boards should include pathologists to ensure appropriate treatment options are considered; (11) all histologic subtypes should be considered potential candidates for chemotherapy; (12) patients with sarcomatoid or biphasic mesothelioma should not be excluded from first-line clinical trials unless there is a compelling reason; (13) tumor subtyping should be further assessed in relation to duration of response to immunotherapy; and (14) systematic screening of all patients for germline mutations is not recommended, in the absence of a family history suspicious for BAP1 syndrome. CONCLUSIONS: These multidisciplinary recommendations for pathology classification and application will allow more informative pathologic reporting and potential risk stratification, to support clinical practice, research investigation and clinical trials.
引用
- Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2019. PMID: 31546041. doi:10.1016/j.jtho.2019.08.2506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。